European Biotech Acquisition Stock Net Asset
| EBACDelisted Stock | USD 11.19 0.10 0.90% |
European Biotech Acquisition fundamentals help investors to digest information that contributes to European Biotech's financial success or failures. It also enables traders to predict the movement of European Stock. The fundamental analysis module provides a way to measure European Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to European Biotech stock.
European |
European Biotech Acquisition Company Net Asset Analysis
European Biotech's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current European Biotech Net Asset | 129.75 M |
Most of European Biotech's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, European Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, European Biotech Acquisition has a Net Asset of 129.75 M. This is much higher than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The net asset for all United States stocks is notably lower than that of the firm.
European Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses European Biotech's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of European Biotech could also be used in its relative valuation, which is a method of valuing European Biotech by comparing valuation metrics of similar companies.European Biotech is currently under evaluation in net asset category among related companies.
European Fundamentals
| Current Valuation | 164.04 M | |||
| Shares Outstanding | 13.21 M | |||
| Shares Owned By Institutions | 72.30 % | |||
| Number Of Shares Shorted | 258.83 K | |||
| Price To Earning | 66.40 X | |||
| Price To Book | 1.34 X | |||
| EBITDA | 342.89 K | |||
| Net Income | 342.89 K | |||
| Cash And Equivalents | 308.1 K | |||
| Cash Per Share | 0.02 X | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | (0.37) X | |||
| Cash Flow From Operations | (514.79 K) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | 0.02 X | |||
| Market Capitalization | 183.5 M | |||
| Total Asset | 129.75 M | |||
| Net Asset | 129.75 M |
About European Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze European Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of European Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of European Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with European Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if European Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in European Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against European Stock
| 0.5 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.46 | PTAIY | Astra International Tbk | PairCorr |
| 0.45 | TLKMF | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to European Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace European Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back European Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling European Biotech Acquisition to buy it.
The correlation of European Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as European Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if European Biotech Acq moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for European Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the European Biotech Acq information on this page should be used as a complementary analysis to other European Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in European Stock
If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |